Serum SHBG levels are not associated with longitudinal cognitive decline in mild cognitive impairment

Manuscript Number: 

16-0513R2

Author(s): 
P. Murali Doraiswamy, Katherine Amy Lin, Colin Rundel

Disclosures

P. Murali Doraiswamy

  • Consulting Fees:
    He has received advisory or speaking fees in the past from Anthrotonix, Muses Labs, Cognoptix, Lundbeck, Takeda, Piramal, Genomind, Sonexa, Targacept, Neurocog Trials.
    Equity:
    He owns shares in Maxwell Health, Muses Labs, Anthrtronix, Evidation and Adverse Events Inc whose products are not discussed here.
    Grants
    • Agency: 
      Elan
    • Agency: 
      Lilly
    • Agency: 
      Neuronetrix
    • Agency: 
      Medivation

Katherine Amy Lin

  • Nothing to Disclose

Colin Rundel

  • Nothing to Disclose